Form 4: Vertex Pharmaceuticals EVP Charles F. Wagner Jr. Reports Stock Disposal
SEC Form 4 Filing
Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, reported the disposal of 2,649 shares of common stock on February 10, 2025, to cover tax obligations.
Summary
- On February 10, 2025, Charles F. Wagner Jr., the EVP & Chief Financial Officer of Vertex Pharmaceuticals, disposed of 2,649 shares of common stock.
- The transaction was executed at a price of $467.98 per share.
- Following the transaction, Wagner directly owns 58,879 shares of Vertex Pharmaceuticals common stock.
- The disposal was related to covering tax obligations.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to insider trading. It doesn't convey any particularly positive or negative sentiment about the company's performance or prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard transaction related to tax obligations.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine disposal of shares by an executive to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of stock disposal transaction |
| 02/12/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.